January 9, 2014 â€“ GlaxoSmithKline Inc. and Theravance Inc. today announced that Anoro Ellipta was approved in Canada on December 23, 2013, for the long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. Anoro Ellipta (umeclidinium/vilanterol) dry powder for inhalation is a combination of a long-acting muscarinic antagonist (LAMA) and a long-acting beta 2-agonist (LABA).

For more details, go to: http://www.gsk.ca/english/html/media-centre/2014-01-09.html